MA38540A1 - Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 - Google Patents

Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Info

Publication number
MA38540A1
MA38540A1 MA38540A MA38540A MA38540A1 MA 38540 A1 MA38540 A1 MA 38540A1 MA 38540 A MA38540 A MA 38540A MA 38540 A MA38540 A MA 38540A MA 38540 A1 MA38540 A1 MA 38540A1
Authority
MA
Morocco
Prior art keywords
beta
alpha
derivatives useful
integrin antagonists
naphthyridine derivatives
Prior art date
Application number
MA38540A
Other languages
English (en)
Other versions
MA38540B1 (fr
Inventor
Niall Andrew Anderson
Brendan John Fallon
John Martin Pritchard
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA38540A1 publication Critical patent/MA38540A1/fr
Publication of MA38540B1 publication Critical patent/MA38540B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

L'invention porte sur un composé de formule (i) ou un sel de celle-ci (i), dans laquelle r1 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle, r2 représente un atome d'hydrogène ou un atome de fluor et r3 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle.
MA38540A 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 MA38540B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305668.4A GB201305668D0 (en) 2013-03-28 2013-03-28 Avs6 Integrin Antagonists
PCT/EP2014/056013 WO2014154725A1 (fr) 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Publications (2)

Publication Number Publication Date
MA38540A1 true MA38540A1 (fr) 2017-02-28
MA38540B1 MA38540B1 (fr) 2017-10-31

Family

ID=48444909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38540A MA38540B1 (fr) 2013-03-28 2014-03-26 Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6

Country Status (38)

Country Link
US (2) US10023568B2 (fr)
EP (2) EP2989100B1 (fr)
JP (1) JP6095847B2 (fr)
KR (2) KR101775085B1 (fr)
CN (1) CN105189499B (fr)
AR (1) AR095768A1 (fr)
AU (1) AU2014243068C1 (fr)
BR (1) BR112015024530A8 (fr)
CA (1) CA2903358A1 (fr)
CL (1) CL2015002860A1 (fr)
CR (1) CR20150509A (fr)
CY (1) CY1120188T1 (fr)
DK (1) DK2989100T3 (fr)
DO (1) DOP2015000251A (fr)
EA (1) EA027305B1 (fr)
ES (1) ES2665597T3 (fr)
GB (1) GB201305668D0 (fr)
HK (1) HK1214262A1 (fr)
HR (1) HRP20180528T1 (fr)
HU (1) HUE036750T2 (fr)
IL (1) IL241184A0 (fr)
LT (1) LT2989100T (fr)
MA (1) MA38540B1 (fr)
ME (1) ME02987B (fr)
MX (1) MX363288B (fr)
NO (1) NO2989100T3 (fr)
NZ (1) NZ629025A (fr)
PE (1) PE20151606A1 (fr)
PH (1) PH12015502232A1 (fr)
PL (1) PL2989100T3 (fr)
PT (1) PT2989100T (fr)
RS (1) RS57220B1 (fr)
SG (1) SG11201506813QA (fr)
SI (1) SI2989100T1 (fr)
TW (1) TWI632143B (fr)
UA (1) UA114952C2 (fr)
UY (1) UY35505A (fr)
WO (1) WO2014154725A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017019412A2 (pt) 2015-03-11 2018-05-02 Glaxosmithkline Ip Dev Ltd proteínas ligadoras de tslp
GB201615588D0 (en) 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
CA3042684A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Amides d'azole et amines en tant qu'inhibiteurs d'integrine .alpha.v
EP3538526B1 (fr) 2016-11-08 2024-04-10 Bristol-Myers Squibb Company Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
LT3538525T (lt) 2016-11-08 2022-09-26 Bristol-Myers Squibb Company Propiono rūgštys, pakeistos 3 padėtyje, kaip alfa v integrino inhibitoriai
AU2017359027A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP7291696B2 (ja) 2017-11-07 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロロピラジン誘導体
WO2019173653A1 (fr) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Composés d'acides aminés et leurs procédés d'utilisation
EA202190134A1 (ru) 2018-06-27 2021-03-26 Плайэнт Терапьютикс, Инк. Соединения аминокислот с неразветвленными линкерами и способы их применения
EP3843728A4 (fr) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
WO2020047208A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
WO2022183360A1 (fr) * 2021-03-02 2022-09-09 Tsao Yeou Ping Peptides synthétiques courts et leurs utilisations pour le traitement de la sécheresse oculaire

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
WO1999030709A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
WO2000072801A2 (fr) 1999-06-02 2000-12-07 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
JP2003502373A (ja) * 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1229910A4 (fr) 1999-10-04 2003-10-01 Merck & Co Inc Antagonistes des recepteurs d'integrine
EP1230240B1 (fr) 1999-11-08 2003-07-23 Merck & Co., Inc. Procede de preparation et intermediaires de preparation d'antagonistes de l'integrine alpha v d'imidazolidinone
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
ES2280383T3 (es) 2000-07-26 2007-09-16 MERCK & CO., INC. Antagonistas de receptores de integrina alfa v.
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
EP1349548A4 (fr) 2001-01-03 2004-06-02 Merck & Co Inc Methodes et compositions de traitement d'une parodontopathie
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
IL164021A0 (en) 2002-03-13 2005-12-18 Univ California Antibodies and anti-pharmaceutical compositions containing the same
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
EP1699512B1 (fr) 2003-11-03 2012-06-20 Glaxo Group Limited Distributeur de fluides
ES2446417T3 (es) 2007-03-23 2014-03-07 Amgen Inc. Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K)
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016219906B2 (en) 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
PH12015502232B1 (en) 2016-02-01
EA027305B1 (ru) 2017-07-31
NO2989100T3 (fr) 2018-07-28
AU2014243068A1 (en) 2015-10-08
EP2989100A1 (fr) 2016-03-02
AU2014243068B2 (en) 2017-01-05
UY35505A (es) 2014-10-31
HRP20180528T1 (hr) 2018-05-04
CN105189499B (zh) 2016-09-28
CR20150509A (es) 2016-03-04
JP6095847B2 (ja) 2017-03-15
CY1120188T1 (el) 2018-12-12
PT2989100T (pt) 2018-05-18
MX2015013742A (es) 2016-02-29
EA201591503A1 (ru) 2016-04-29
SI2989100T1 (en) 2018-06-29
AU2014243068C1 (en) 2017-05-25
US20160280705A1 (en) 2016-09-29
DK2989100T3 (en) 2018-04-23
RS57220B1 (sr) 2018-07-31
UA114952C2 (uk) 2017-08-28
EP2989100B1 (fr) 2018-02-28
PL2989100T3 (pl) 2018-07-31
GB201305668D0 (en) 2013-05-15
PE20151606A1 (es) 2015-11-24
TWI632143B (zh) 2018-08-11
CA2903358A1 (fr) 2014-10-02
ME02987B (fr) 2018-10-20
US20180291022A1 (en) 2018-10-11
ES2665597T3 (es) 2018-04-26
SG11201506813QA (en) 2015-10-29
MA38540B1 (fr) 2017-10-31
HUE036750T2 (hu) 2018-07-30
WO2014154725A1 (fr) 2014-10-02
EP3360876A1 (fr) 2018-08-15
JP2016515557A (ja) 2016-05-30
KR101775085B1 (ko) 2017-09-05
AR095768A1 (es) 2015-11-11
KR20170103033A (ko) 2017-09-12
KR20150135790A (ko) 2015-12-03
NZ629025A (en) 2017-05-26
CL2015002860A1 (es) 2016-03-28
TW201533042A (zh) 2015-09-01
CN105189499A (zh) 2015-12-23
BR112015024530A2 (pt) 2017-07-18
US10450312B2 (en) 2019-10-22
PH12015502232A1 (en) 2016-02-01
KR102042141B1 (ko) 2019-11-07
US10023568B2 (en) 2018-07-17
LT2989100T (lt) 2018-05-25
HK1214262A1 (zh) 2016-07-22
DOP2015000251A (es) 2016-02-29
MX363288B (es) 2019-03-19
BR112015024530A8 (pt) 2019-12-10
IL241184A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
MA38540A1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA35172B1 (fr) Melanges pestticides contenant des derives d'isoxazoline
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MY177250A (en) Novel nicotinamide derivative or salt thereof
MY156669A (en) Pesticidal composition and its use
EA201491936A1 (ru) Азотсодержащее гетероциклическое соединение
RS54730B1 (sr) Inhibitori beta sekretaze
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
BR112012027378A2 (pt) composto pesticida e seu uso
BR112018004447A2 (pt) derivado de biarila e medicamento contendo o mesmo
BR112013015604A2 (pt) novo derivado de isoquinolina substituído
MA39305A3 (fr) Dérivés d'éthynyle
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5
IN2012DN01251A (fr)
MA20150280A2 (fr) Dérivés d'aryléthynyle
RS53032B (en) DIHIDRO-OXAZOLOBENZODIAZEPINONE DERIVATIVES, PROCEDURES FOR THEIR PRODUCTION AND THE PHARMACEUTICAL MIXTURES CONTAINING THESE COMPOUNDS
MX2016016765A (es) Repelente de animales roedores.
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина